PCR

Researchers evaluated combination immunotherapy with standard chemotherapy in high-risk HER2-negative breast cancer. The regimen increased pathologic complete response rates but led to more frequent immune-related adverse events.

Cell and gene therapies have expanded rapidly over the last decade; however, affordably manufacturing sufficient quantities remains a challenge. In this article, learn more about the development challenges shaping the future of advanced therapies.

A highly sensitive blood test targeting KRAS mutations is uncovering pancreatic cancer patients at high risk of recurrence that standard testing fails to detect.

This article explores how new technologies in plasma proteomics enable the simultaneous analysis of thousands of proteins, improving early disease detection, biomarker discovery, and precision medicine despite ongoing challenges.

New research introduces INTACT, a tool that combines RNA sensing and blood-based reporters to track gene expression in real time. The system could eventually enable large-scale monitoring of genes across multiple tissues.

Researchers at Lund University have validated a blood-based method for measuring circulating tumor DNA in patients with early breast cancer.